Doxycycline (Systemic — Ocular Rosacea / Blepharitis)
Brand names: Vibramycin, Efracea (low-dose licensed for rosacea)
This entry covers systemic (oral) doxycycline, a tetracycline antibiotic, used at anti-inflammatory dosing for chronic blepharitis, meibomian gland dysfunction and ocular rosacea rather than for treating an ocular infection.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Beyond its antibacterial inhibition of ribosomal protein synthesis, low-dose doxycycline exerts an anti-inflammatory effect by inhibiting matrix metalloproteinases and reducing lipase activity that destabilises the tear film lipid layer.
Prescribing in practice
- Doxycycline is contraindicated in pregnancy, breastfeeding and children under twelve because tetracyclines cause permanent dental staining and affect developing bone.
- It is photosensitising, so patients should be warned about exaggerated sunburn and advised on sun protection.
- To reduce the risk of oesophageal irritation and ulceration, doses should be swallowed whole with plenty of water while sitting or standing and not immediately before lying down.
Monitoring
Routine laboratory monitoring is not usually required for short anti-inflammatory courses, but clinical review of symptom response and tolerability guides duration of therapy.
Counselling the patient
- Take with a full glass of water and stay upright afterwards to protect the gullet.
- Use sunscreen and cover up, as your skin will burn more easily.
- Improvement in eye comfort may take several weeks, so persist with the course as directed.
Evidence & guidelines
Sub-antimicrobial and anti-inflammatory tetracycline dosing for meibomian gland dysfunction and ocular rosacea is supported by long-standing ophthalmology and dermatology practice.
Reference: DEWS II Blepharitis Guidelines; NICE Rosacea Guidance; MHRA Tetracycline + Retinoid Warning; SPC Efracea / Vibramycin; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme